Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes - 22/03/19

Doi : 10.1016/j.therap.2018.09.074

Francesco Salvo ^a,^b,^⁎ , Jean-Luc Faillie ^c,^d
^a Service de pharmacologie médicale, université de Bordeaux, UMR 1219, 33076 Bordeaux cedex, France
^b Service de pharmacologie médicale, pôle de santé publique, CHU de Bordeaux, 33000 Bordeaux, France
^c Department of medical pharmacology and toxicology, CHU Montpellier university hospital, 34090 Montpellier, France
^d Laboratory of biostatistics, epidemiology and public health (EA 2415), faculty of medicine, university of Montpellier, 34090 Montpellier, France

^⁎Corresponding author. Service de pharmacologie médicale, université de Bordeaux, UMR 1219, 146 rue Léo-Saignat, 33076 Bordeaux cedex, France.Service de pharmacologie médicale, université de Bordeaux, UMR 1219146 rue Léo-SaignatBordeaux cedex33076France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	6
Iconographies	0
Vidéos	0
Autres	0

Summary

In the field of diabetes, pharmacoepidemiologic (PE) studies are numerous and represent an essential tool to assess the real life effects of diabetes drugs. However, the specificity of the study of drugs used in diabetes, characterized by a high frequency of switches, interruptions and add-on, must be kept in mind by pharmacoepidemiologists in order to perform well-conducted studies and avoid several biases. In this article, the authors discussed the specific interest of PE studies in the field of diabetes, provide a brief overview of biases that can affect those studies, and suggest pragmatic solutions for more correct results and appropriate interpretation.

Le texte complet de cet article est disponible en PDF.

Keywords : Diabetes mellitus, Pharmacoepidemiology, Post-marketing surveillance, Real-world evidence, Database studies